EU Approves AstraZeneca's CALQUENCE for First-Line CLL
Ticker: AZN · Form: 6-K · Filed: 2025-06-06T00:00:00.000Z
Sentiment: bullish
Topics: regulatory-approval, pharmaceuticals, oncology, europe
Related Tickers: AZN
TL;DR
EU greenlights AstraZeneca's CALQUENCE for 1st-line CLL, a big win for patients and AZ.
AI Summary
AstraZeneca PLC announced on June 6, 2025, that the European Commission has approved a fixed-duration regimen of CALQUENCE (acalabrutinib) for the first-line treatment of adult patients with Chronic Lymphocytic Leukemia (CLL). This approval marks a significant advancement in CLL treatment options available in the EU.
Why It Matters
This approval provides a new, potentially less burdensome treatment option for newly diagnosed CLL patients in the EU, improving their quality of life and treatment outcomes.
Risk Assessment
Risk Level: low — The filing is an announcement of regulatory approval, which is generally positive news with low inherent risk.
Key Players & Entities
- AstraZeneca PLC (company) — Filer of the report and developer of the drug
- CALQUENCE (acalabrutinib) (drug) — The medication that received approval
- European Commission (company) — Regulatory body that granted the approval
- Chronic Lymphocytic Leukemia (CLL) (medical_condition) — The disease for which CALQUENCE is approved
- June 6, 2025 (date) — Date of the announcement
FAQ
What specific fixed-duration regimen of CALQUENCE was approved?
The filing states approval for a 'fixed-duration regimen' of CALQUENCE, but does not specify the exact duration or dosage in this report.
What is the significance of this approval for first-line CLL treatment?
This approval offers a new first-line treatment option for adult patients with CLL in the EU, potentially improving outcomes and patient experience.
Which regulatory body granted the approval for CALQUENCE?
The European Commission granted the approval for the fixed-duration regimen of CALQUENCE.
When was this announcement made?
The announcement was made on June 6, 2025.
Is this approval for all types of CLL or specific patient populations?
The approval is for adult patients with Chronic Lymphocytic Leukemia (CLL) in the first-line setting.
From the Filing
0001654954-25-006655.txt : 20250606 0001654954-25-006655.hdr.sgml : 20250606 20250606075249 ACCESSION NUMBER: 0001654954-25-006655 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250606 FILED AS OF DATE: 20250606 DATE AS OF CHANGE: 20250606 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 251028907 BUSINESS ADDRESS: STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a7065l.htm FIXED-DURATION CALQUENCE APPROVED IN EU FOR 1L CLL a7065l  FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of June 2025   Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F X Form 40-F __   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______   Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.   Yes __ No X   If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________       AstraZeneca PLC   INDEX TO EXHIBITS     1. Fixed-duration Calquence approved in EU for 1L CLL   06 June 2025   Fixed-duration  Calquence -based regimens approved in EU for patients with chronic lymphocytic leukaemia in the 1st-line setting   AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations   A fixed-duration regimen of AstraZeneca's  Calquence  (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been approved in the European Union (EU) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).   The approval by the European Commission follows the  positive opinion  of the Committee for Medicinal Products for Human Use and was based on positive results from the pivotal  AMPLIFY Phase III trial , presented at the American Society of Hematology 2024 Annual Meeting and published in  The New England Journal of Medicine . 1   Results from the AMPLIFY trial showed 77% of patients treated with  Calquence  plus venetoclax and 83% of patients treated with  Calquence  plus venetoclax and obinutuzumab were progression free at three years, versus 67% of patients treated with standard-of-care chemoimmunotherapy (investigator's choice of fludarabine-cyclophosphamide-rituximab or bendamustine-rituximab). 1  Median progression-free survival (PFS) was not reached for either experimental arm versus 47.6 months for chemoimmunotherapy.